On May 30, President Trump promised that “some” of the big drug makers would announce “voluntary, massive drops in prices” in two weeks.
But not everyone in the pharmaceutical industry got the memo.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
And the patient is the one caught in the middle
Oh, so true! A co-worker just got a medication for her psoriasis, it came in the form of injections and it was 2 syringes, to the tune of 33,000! Thank goodness she has excellent insurance and paid 35.00.
Oddly, the Pfizer produced generic for Viagra is not mentioned – that might have a cost impact.